Genomic profile, smoking, and response to anti-PD-1 therapy in non-small cell lung carcinoma.
The recent successes of immune checkpoint therapies have established a new era for the treatment of patients with cancer, yet the predictors of response remain largely undetermined. We recently demonstrated that the genomic landscape of lung cancers substantially influences the response to programmed cell death 1 receptor (PD-1) blockade, providing new insights into the molecular determinants of the response to immunotherapy.
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell Medical College, New York, NY.
Matthew
M
Hellmann
Division of Hematology/Oncology, New York Presbyterian/Columbia University Hospital , New York, NY.
Naiyer
N
Rizvi
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell Medical College, New York, NY.
Jedd D
JD
Wolchok
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center , New York, NY.
Timothy A
TA
Chan
Cancer; immunotherapy; lung; mutation